US1538678A
(en)
*
|
1923-02-24 |
1925-05-19 |
Joseph S Blinn |
Suppository injector
|
US3791385A
(en)
*
|
1972-10-16 |
1974-02-12 |
A Davis |
Catamenial device and applicator thereof
|
CA1339210C
(en)
|
1988-05-31 |
1997-08-05 |
John Lewicki |
Recombinant techniques for production of novel natriuretic and vasodilator peptides
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
DK0478797T3
(da)
|
1990-04-20 |
1995-06-26 |
Hisayuki Matsuo |
Nyt fysiologisk aktivt peptid stammende fra gris
|
JP2930380B2
(ja)
|
1990-07-13 |
1999-08-03 |
壽之 松尾 |
ブタ由来新規生理活性ペプチド(cnp―53)
|
JP3026351B2
(ja)
|
1990-07-13 |
2000-03-27 |
壽之 松尾 |
ブタcnp遺伝子及び前駆体蛋白
|
JP2977159B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
カエル由来新規生理活性ペプチド(カエルcnp)
|
JP2977158B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
トリ由来新規生理活性ペプチド(ニワトリcnp)
|
JP3026352B2
(ja)
|
1990-09-11 |
2000-03-27 |
壽之 松尾 |
ラットCNPcDNA及び前駆体蛋白
|
JP3026354B2
(ja)
|
1990-09-27 |
2000-03-27 |
壽之 松尾 |
ヒトcnp遺伝子及び前駆体蛋白
|
JP2809533B2
(ja)
|
1991-01-31 |
1998-10-08 |
壽之 松尾 |
Cnp類似体ペプチド
|
AU662155B2
(en)
*
|
1991-05-10 |
1995-08-24 |
Celtrix Pharmaceuticals, Inc. |
Targeted delivery of bone growth factors
|
AU6360394A
(en)
|
1993-03-03 |
1994-09-26 |
Mayo Foundation For Medical Education And Research |
Vasonatrin peptide and analogs thereof
|
WO1995005455A1
(en)
*
|
1993-08-13 |
1995-02-23 |
Rijksuniversiteit Te Groningen |
Pharmaceutical composition comprising phosphatase or a derivative thereof
|
US5665704A
(en)
|
1993-11-12 |
1997-09-09 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
WO1995013296A1
(en)
|
1993-11-12 |
1995-05-18 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
US5846932A
(en)
|
1993-11-12 |
1998-12-08 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
US6525022B1
(en)
|
1993-11-12 |
2003-02-25 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
AU2671795A
(en)
|
1994-06-02 |
1996-01-04 |
Boehringer Mannheim Gmbh |
Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments
|
JPH0870875A
(ja)
|
1994-09-05 |
1996-03-19 |
Tosoh Corp |
組換えアルカリフォスファタ−ゼ融合タンパク質
|
US5863782A
(en)
*
|
1995-04-19 |
1999-01-26 |
Women's And Children's Hospital |
Synthetic mammalian sulphamidase and genetic sequences encoding same
|
US6028055A
(en)
|
1996-10-22 |
2000-02-22 |
Genetech, Inc. |
Receptor selective BNP
|
EP0939770A1
(en)
|
1996-10-22 |
1999-09-08 |
Genentech, Inc. |
Receptor specific brain natriuretic peptide (bnp)
|
CA2280957A1
(en)
*
|
1997-02-14 |
1998-08-20 |
Leslie Orgel |
Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
|
CA2321026A1
(en)
|
1998-03-09 |
1999-09-16 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
CA2245903A1
(en)
*
|
1998-09-28 |
2000-03-28 |
Mcgill University |
Use of pex in the treatment of metabolic bone diseases
|
CA2260376A1
(en)
|
1999-02-11 |
2000-08-11 |
Universite De Montreal |
New metalloproteases of the neprilysin family
|
CA2262056A1
(en)
|
1999-02-24 |
2000-08-24 |
Guy Boileau |
Composition, methods and reagents for the synthesis of a soluble form of human pex
|
AU2495200A
(en)
|
1999-03-08 |
2000-09-28 |
Genentech Inc. |
Compositions and methods for the treatment of tumor
|
AU772074B2
(en)
|
1999-04-28 |
2004-04-08 |
Vectramed, Inc. |
Enzymatically activated polymeric drug conjugates
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
JP2000327583A
(ja)
*
|
1999-05-17 |
2000-11-28 |
Medei Sci Puraningu:Kk |
骨指向性ホルモン誘導体
|
CA2499211A1
(en)
|
1999-05-17 |
2000-11-23 |
Conjuchem Inc. |
Modified peptides yy and conjugates thereof
|
US20040266673A1
(en)
|
2002-07-31 |
2004-12-30 |
Peter Bakis |
Long lasting natriuretic peptide derivatives
|
DE19942230C2
(de)
|
1999-09-03 |
2003-09-25 |
Wolf-Georg Forssmann |
Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen
|
AU1920201A
(en)
|
1999-11-16 |
2001-05-30 |
Genzyme Corporation |
Improved regulatory elements for delivery to the liver
|
US20020132819A1
(en)
|
1999-12-17 |
2002-09-19 |
Metcalf Chester A. |
Novel purinse
|
US6407211B1
(en)
|
1999-12-17 |
2002-06-18 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic peptides
|
JP4237375B2
(ja)
|
2000-03-31 |
2009-03-11 |
アスビオファーマ株式会社 |
虚血性疾患の処置又は予防に用いる医薬組成物
|
EP1502604A1
(en)
|
2000-04-26 |
2005-02-02 |
Cellegy Pharmaceuticals, Inc |
Use of nitric oxide mimetics in cancer treatment
|
US7678391B2
(en)
|
2000-04-26 |
2010-03-16 |
Queen's University At Kingston |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
AU5022101A
(en)
|
2000-04-26 |
2001-11-07 |
Univ Kingston |
Formulations and methods of using nitric oxide mimetics against a malignant cellphenotype
|
US20050142217A1
(en)
|
2000-04-26 |
2005-06-30 |
Adams Michael A. |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
US6830885B1
(en)
|
2000-08-18 |
2004-12-14 |
Phenogene Therapeutiques Inc. |
Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
|
CA2418461A1
(en)
*
|
2000-08-23 |
2002-02-28 |
Biomep Inc. |
Method and compositions for promoting osteogenesis
|
US6436386B1
(en)
|
2000-11-14 |
2002-08-20 |
Shearwater Corporation |
Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
|
EA005584B1
(ru)
|
2000-12-07 |
2005-04-28 |
Эли Лилли Энд Компани |
Слитые белки glp-1
|
JP2002178279A
(ja)
|
2000-12-12 |
2002-06-25 |
Ulvac Japan Ltd |
基板搬送方法
|
AU2002255478A1
(en)
*
|
2001-01-10 |
2002-09-12 |
Pe Corporation (Ny) |
Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
|
JP2002246704A
(ja)
|
2001-02-16 |
2002-08-30 |
Philips Japan Ltd |
電子装置及び回路装置
|
IL142118A0
(en)
|
2001-03-20 |
2002-03-10 |
Prochon Biotech Ltd |
Method and composition for treatment of skeletal dysplasias
|
AU2002258592A1
(en)
*
|
2001-03-23 |
2002-11-25 |
The Burnham Institute |
Compositions and methods for modulating bone mineral deposition
|
US7888372B2
(en)
*
|
2001-03-23 |
2011-02-15 |
National Institutes Of Health (Nih) |
Compositions and methods for modulating bone mineral deposition
|
US6808905B2
(en)
*
|
2001-05-14 |
2004-10-26 |
Cell Genesys, Inc. |
Lentiviral vectors encoding clotting factors for gene therapy
|
ATE421091T1
(de)
|
2001-07-16 |
2009-01-15 |
Caprotec Bioanalytics Gmbh |
Fangverbindungen, ihre entnahme und verfahren zur analysierung des proteoms und von komplexen zusammensetzungen
|
US6610025B2
(en)
*
|
2001-08-06 |
2003-08-26 |
The Procter & Gamble Company |
Tampon applicator arrangement
|
BRPI0203172B8
(pt)
|
2001-09-28 |
2021-05-25 |
Nakao Kazuwa |
composição farmacêutica para acondroplasia
|
US20050202442A1
(en)
|
2003-12-15 |
2005-09-15 |
Morris David W. |
Novel therapeutic targets in cancer
|
CA2469972A1
(en)
|
2001-12-20 |
2003-07-03 |
Phenogene Therapeutiques Inc. |
Bone polypeptide-1
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
WO2003060071A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20030158132A1
(en)
*
|
2002-01-22 |
2003-08-21 |
Genvec, Inc. |
Method for enhancing bone density or formation
|
WO2003074082A1
(en)
|
2002-03-06 |
2003-09-12 |
Cellegy Pharmaceuticals, Inc. |
Formulations and methods of using nitric oxide mimetics in cancer treatment
|
AU2003214214A1
(en)
|
2002-03-18 |
2003-10-08 |
Scios Inc. |
Method for treating congestive heart failure
|
US20050113286A1
(en)
|
2002-03-18 |
2005-05-26 |
Schreiner George F. |
Methods for treating congestive heart failure
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
CA2433479A1
(en)
*
|
2002-07-22 |
2004-01-22 |
F. Hoffmann-La Roche Ag |
Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
|
AU2003246500A1
(en)
|
2002-07-31 |
2004-02-16 |
Conjuchem Biotechnologies Inc. |
Long lasting natriuretic peptide derivatives
|
AU2003270427A1
(en)
|
2002-09-06 |
2004-03-29 |
University Of South Florida |
Cellular delivery of natriuretic peptides
|
WO2004046194A2
(en)
|
2002-11-18 |
2004-06-03 |
Syn X Pharma, Inc. |
Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
|
DE60331584D1
(de)
|
2002-11-26 |
2010-04-15 |
Biocon Ltd |
Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
|
US7648962B2
(en)
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
US7105539B2
(en)
|
2002-12-03 |
2006-09-12 |
Enobia Pharma |
Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
|
EP1583554A2
(en)
|
2003-01-13 |
2005-10-12 |
Gudrun Rappold-Hoerbrand |
Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
|
US20060228710A1
(en)
|
2003-02-14 |
2006-10-12 |
Morris David W |
Novel therapeutic targets in cancer
|
US7488713B2
(en)
|
2004-03-18 |
2009-02-10 |
University Of South Florida |
Cancer treatment using C-type natriuretic peptides
|
US7341838B2
(en)
|
2003-04-17 |
2008-03-11 |
Biosite Incorporated |
Polypeptides related to natriuretic peptides and methods of their identification and use
|
CA2527878A1
(en)
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
ATE490469T1
(de)
|
2003-06-17 |
2010-12-15 |
Otago Innovation Ltd |
Beurteilung des skelettwachstums unter verwendung von messungen von nt-cnp-peptiden
|
EP1638443B1
(en)
|
2003-06-20 |
2010-10-20 |
Mayo Foundation For Medical Education And Research |
Isoforms of brain natriuretic peptide
|
WO2005052593A1
(en)
|
2003-10-29 |
2005-06-09 |
The University Of Leicester |
Detection
|
US7431915B2
(en)
|
2003-10-31 |
2008-10-07 |
The Regents Of The University Of California |
Peptides whose uptake by cells is controllable
|
ES2378167T3
(es)
|
2003-11-13 |
2012-04-09 |
Hanmi Holdings Co., Ltd |
Complejo de proteína que utiliza fragmento de inmunoglobulina y el método para su preparación
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
WO2005070446A1
(en)
|
2004-01-15 |
2005-08-04 |
Scios Inc. |
Method for treating cardiac remodeling following myocardial injury
|
AU2005207886A1
(en)
|
2004-01-27 |
2005-08-11 |
Compugen Usa, Inc. |
Novel brain natriuretic peptide variants and methods of use thereof
|
US20080182299A1
(en)
|
2004-01-27 |
2008-07-31 |
Compugent Ltd. |
Novel brain natriuretic peptide variants and methods of use thereof
|
JP4825667B2
(ja)
|
2004-03-31 |
2011-11-30 |
一和 中尾 |
関節炎症治療剤又は予防剤
|
KR20070007842A
(ko)
|
2004-03-31 |
2007-01-16 |
카즈와 나카오 |
신장증가용 조성물
|
JP2005292718A
(ja)
|
2004-04-05 |
2005-10-20 |
Furukawa Electric Co Ltd:The |
光導波路、光導波路モジュールおよび光導波路の作成方法
|
PL1759001T3
(pl)
*
|
2004-04-21 |
2011-09-30 |
Alexion Pharma Inc |
Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
|
KR20070038460A
(ko)
|
2004-05-10 |
2007-04-10 |
노바세아, 인크. |
활성 비타민 디(d) 화합물을 이용한 동맥 재협착의 예방
|
US7863238B2
(en)
*
|
2004-06-10 |
2011-01-04 |
Saint Louis University |
Proteins with an attached short peptide of acidic amino acids
|
US7972593B2
(en)
*
|
2004-06-10 |
2011-07-05 |
Saint Louis University |
Delivery of therapeutic agents to the bone
|
US20070081984A1
(en)
*
|
2005-10-11 |
2007-04-12 |
Shunji Tomatsu |
Compositions and methods for treating hypophosphatasia
|
US20070081986A1
(en)
|
2005-10-07 |
2007-04-12 |
Shunji Tomatsu |
Beta-glucuronidase with an attached short peptide of acidic amino acids
|
ATE496060T1
(de)
|
2004-07-15 |
2011-02-15 |
Univ Queensland |
Proteinartige verbindungen und anwendungen davon
|
WO2006039480A2
(en)
|
2004-09-29 |
2006-04-13 |
The Burnham Institute For Medical Research |
Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification
|
EP1827502A4
(en)
|
2004-12-01 |
2008-01-16 |
Genzyme Corp |
PROCESS FOR THE TARGETED DELIVERY OF GENETIC MATERIAL TO THE LIVER
|
PT2510942E
(pt)
|
2005-04-07 |
2015-12-28 |
Cardiorentis Ag |
Utilização de péptido natriurético para o tratamento de insuficiência cardíaca
|
WO2006116260A2
(en)
|
2005-04-26 |
2006-11-02 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
US20070042957A1
(en)
|
2005-08-19 |
2007-02-22 |
Mayo Foundation For Medical Education And Research |
Type v phosphodiesterase inhibitors and natriuretic polypeptides
|
US7470668B2
(en)
|
2005-08-24 |
2008-12-30 |
Enobia Pharma Inc. |
Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
|
US20070099831A1
(en)
|
2005-09-06 |
2007-05-03 |
Paul Morley |
Parathyroid hormone analogues and methods of use
|
WO2007035600A2
(en)
*
|
2005-09-16 |
2007-03-29 |
Mayo Foundation For Education And Research |
Natriuretic activities
|
WO2007041645A2
(en)
|
2005-10-03 |
2007-04-12 |
Scios Inc. |
Oxidized human bnp
|
RU2316334C2
(ru)
|
2005-12-19 |
2008-02-10 |
Медитек Индастриз ЛЛС |
Способ активации утраченных двигательных функций, а также определения эффективности их восстановления при повреждении центральной нервной системы
|
US7625564B2
(en)
*
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
JP5576610B2
(ja)
|
2006-02-20 |
2014-08-20 |
フィロジカ リミテッド |
ペプチド構造のライブラリーの構築およびスクリーニング方法
|
US8784833B2
(en)
|
2006-06-27 |
2014-07-22 |
Saint Louis University |
Prenatal enzyme replacement therapy for hypophosphatasia
|
EP2040758A4
(en)
|
2006-06-30 |
2014-09-17 |
Interface Biologics Inc |
BIORESPONSIVE POLYMERS
|
JP5702930B2
(ja)
|
2006-08-08 |
2015-04-15 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
利尿ポリペプチドおよびナトリウム利尿ポリペプチド
|
US7825092B2
(en)
|
2006-08-08 |
2010-11-02 |
University Of South Florida |
Dendroaspis natriuretic peptide for treatment of cancer
|
US8283318B2
(en)
|
2006-09-08 |
2012-10-09 |
Mayo Foundation For Medical Education And Research |
Aquaretic and natriuretic polypeptides lacking vasodilatory activity
|
AU2007292903B2
(en)
|
2006-09-08 |
2012-03-29 |
Ambrx, Inc. |
Modified human plasma polypeptide or Fc scaffolds and their uses
|
US7825093B2
(en)
|
2006-10-25 |
2010-11-02 |
Amgen Inc. |
Methods of using OSK1 peptide analogs
|
WO2008058016A2
(en)
|
2006-11-02 |
2008-05-15 |
University Of Virginia Patent Foundation |
Ethoid-containing compounds, methods for preparing ethoid-containing compounds, and methods for use
|
CN103961686A
(zh)
|
2006-11-16 |
2014-08-06 |
凯制药公司 |
用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
|
US20080181903A1
(en)
|
2006-12-21 |
2008-07-31 |
Pdl Biopharma, Inc. |
Conjugate of natriuretic peptide and antibody constant region
|
EP2118665B1
(en)
|
2007-03-12 |
2012-04-18 |
Biomedica Medizinprodukte GmbH & Co KG |
Diagnosis of septic complications
|
EP1985697A1
(en)
|
2007-04-27 |
2008-10-29 |
AM-Pharma B.V. |
Modified phosphatases
|
KR20080098216A
(ko)
|
2007-05-04 |
2008-11-07 |
한미약품 주식회사 |
캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
|
PT2158319E
(pt)
|
2007-05-11 |
2012-03-06 |
Enobia Canada Ltd Partnership |
Fosfatase alcalina dirigida ao osso, kits e métodos para a utilização da mesma
|
CN101802197A
(zh)
|
2007-05-14 |
2010-08-11 |
比奥根艾迪克Ma公司 |
单链FC(ScFc)区、包含其的结合多肽及与其相关的方法
|
JP2010530222A
(ja)
|
2007-06-06 |
2010-09-09 |
べーリンガー インゲルハイム インターナショナル ゲーエムベーハー |
ナトリウム利尿融合タンパク質
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
WO2009006520A1
(en)
|
2007-07-03 |
2009-01-08 |
Medimmune, Llc |
Hinge domain engineering
|
JP2010532323A
(ja)
|
2007-07-06 |
2010-10-07 |
セラテクノロジーズ インコーポレイテッド |
アルファ−メラニン細胞刺激ホルモン(アルファ−msh)および心房性ナトリウム利尿タンパク質(anp)の二機能性融合タンパク質ならびに高血圧および急性腎臓損傷における使用
|
EP2171053B1
(en)
|
2007-07-20 |
2014-04-23 |
Mayo Foundation for Medical Education and Research |
Natriuretic polypeptides
|
US20090053192A1
(en)
|
2007-08-10 |
2009-02-26 |
Burnham Institute For Medical Research |
Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
|
WO2009023270A2
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
JP2010539056A
(ja)
|
2007-09-11 |
2010-12-16 |
モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト |
治療剤としてのcnp−22単独、またはフィサレミンとの組合せの使用
|
WO2009034134A2
(en)
|
2007-09-11 |
2009-03-19 |
Pharis Biotec Gmbh |
Use of natriuretic peptides for treating angioedema syndromes
|
JP2010539053A
(ja)
|
2007-09-11 |
2010-12-16 |
モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト |
単独でまたはペンタガストリンと組み合わせて用いる、治療剤としてのγ1MSH
|
WO2009033683A2
(en)
|
2007-09-11 |
2009-03-19 |
Mondobiotech Laboratories Ag |
Galanin message associated peptide alone or in combination with minigastrin as a therapeutic agent
|
EP2187941A2
(en)
|
2007-09-11 |
2010-05-26 |
Mondobiotech Laboratories AG |
Use of a galanin peptide as a therapeutic agent
|
AU2008297908A1
(en)
*
|
2007-09-11 |
2009-03-19 |
Mondobiotech Laboratories Ag |
Use of a peptide as a therapeutic agent
|
US8357656B2
(en)
|
2007-09-15 |
2013-01-22 |
Mayo Foundation For Medical Education And Research |
Natriuretic peptide receptor-C agonists
|
TWI367213B
(en)
|
2007-11-21 |
2012-07-01 |
Biomarin Pharm Inc |
Variants of c-type natriuretic peptide
|
WO2009086126A2
(en)
|
2007-12-21 |
2009-07-09 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
EP2080812A1
(en)
|
2008-01-18 |
2009-07-22 |
Transmedi SA |
Compositions and methods of detecting post-stop peptides
|
EP2277890B1
(en)
|
2008-05-23 |
2016-01-06 |
Daiichi Sankyo Company, Limited |
Peptide capable of extending half-life of peptide of interest in plasma
|
KR20110020903A
(ko)
|
2008-06-06 |
2011-03-03 |
메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 |
키메라 나트륨이뇨성 폴리펩티드 및 심장 리모델링 억제 방법
|
WO2009156481A1
(en)
|
2008-06-25 |
2009-12-30 |
Ascendis Pharma As |
Pegylated bnp
|
CA2729100C
(en)
|
2008-06-26 |
2018-01-02 |
Acceleron Pharma Inc. |
Methods for dosing an activin-actriia antagonist and monitoring of treated patients
|
EP2307447B1
(en)
|
2008-07-02 |
2016-03-09 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides with unique pharmacologic profiles
|
ES2523043T3
(es)
|
2008-07-23 |
2014-11-20 |
Hanmi Science Co., Ltd. |
Un complejo polipeptídico que comprende un polímero no peptidílico que tiene tres extremos funcionales
|
US20100093678A1
(en)
|
2008-10-10 |
2010-04-15 |
The University Of Georgia Research Foundation, Inc |
Compositions and methods of the treatment of obesity and osteoporosis
|
WO2010048308A2
(en)
|
2008-10-24 |
2010-04-29 |
Deborah Dickey |
Natriuretic polypeptides
|
US8455438B2
(en)
|
2008-12-29 |
2013-06-04 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides for reducing or preventing restenosis
|
TW201031752A
(en)
|
2009-01-19 |
2010-09-01 |
Hanmi Pharm Ind Co Ltd |
Method for producing physiologically active protein or peptide using immunoglobulin fragment
|
US20120093814A1
(en)
|
2009-03-30 |
2012-04-19 |
Boehringer Ingelheim International Gmbh |
Fusion Proteins Comprising Canine FC Portions
|
WO2010129655A2
(en)
|
2009-05-05 |
2010-11-11 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides having mutations within their disulfide rings
|
EP3175863B1
(en)
|
2009-05-20 |
2021-12-01 |
BioMarin Pharmaceutical Inc. |
Variants of c-type natriuretic peptide
|
JP5986986B2
(ja)
|
2010-04-30 |
2016-09-06 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
基質石灰化障害を治療する方法、組成物、およびキット
|
CA2823066A1
(en)
|
2010-12-27 |
2012-07-05 |
Alexion Pharma International Sarl |
Compositions comprising natriuretic peptides and methods of use thereof
|
CA2852874A1
(en)
|
2011-10-19 |
2013-04-25 |
Alexion Pharma Holding |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
WO2013071262A1
(en)
|
2011-11-10 |
2013-05-16 |
Kai Pharmaceuticals, Inc. |
Calcimimetics and methods for their use
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
BR112015001712A2
(pt)
|
2012-07-25 |
2017-07-04 |
Psioxus Therapeutics Ltd |
uso de s-pindolol para o tratamento da caquexia e sarcopenia
|
CN112029753A
(zh)
|
2014-01-24 |
2020-12-04 |
安-法玛公司 |
碱性磷酸酶的下游处理
|
ES2851674T3
(es)
|
2014-06-09 |
2021-09-08 |
Ultragenyx Pharmaceutical Inc |
Control efectivo y eficaz de fosfato sérico para una formación ósea óptima
|
US10822596B2
(en)
|
2014-07-11 |
2020-11-03 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for treating craniosynostosis
|
MX2017007392A
(es)
|
2014-12-05 |
2019-01-24 |
Alexion Pharma Inc |
Tratamiento de convulsiones con fosfatasa alcalina recombinante.
|
US10603361B2
(en)
|
2015-01-28 |
2020-03-31 |
Alexion Pharmaceuticals, Inc. |
Methods of treating a subject with an alkaline phosphatase deficiency
|
CN108350440A
(zh)
|
2015-08-17 |
2018-07-31 |
阿雷克森制药公司 |
碱性磷酸酯的制造
|
EP3355904A4
(en)
|
2015-09-28 |
2019-06-12 |
Alexion Pharmaceuticals, Inc. |
IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
|
US11400140B2
(en)
|
2015-10-30 |
2022-08-02 |
Alexion Pharmaceuticals, Inc. |
Methods for treating craniosynostosis in a patient
|
EP3426286A4
(en)
|
2016-03-08 |
2019-12-04 |
Alexion Pharmaceuticals, Inc. |
METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN
|
WO2017173395A1
(en)
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
WO2017171871A1
(en)
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
CA3019726A1
(en)
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Treating muscle weakness with alkaline phosphatases
|
EP3464573A4
(en)
|
2016-06-06 |
2020-02-19 |
Alexion Pharmaceuticals, Inc. |
IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES
|
ES2887573T3
(es)
|
2016-06-27 |
2021-12-23 |
Alexion Pharma Inc |
Métodos para el tratamiento de la hipofosfatasia en niños y adolescentes
|
US11116821B2
(en)
|
2016-08-18 |
2021-09-14 |
Alexion Pharmaceuticals, Inc. |
Methods for treating tracheobronchomalacia
|